Targeted Drug Delivery: Trends and Perspectives.
Ashique S, Sandhu NK, Chawla V, Chawla PA.
Curr Drug Deliv. 2021;18(10):1435-1455. doi: 10.2174/1567201818666210609161301.
G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery.
Zhang M, Chen T, Lu X, Lan X, Chen Z, Lu S.
Signal Transduct Target Ther. 2024 Apr 10;9(1):88. doi: 10.1038/s41392-024-01803-6.
Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs.
Choi HY, Chang JE.
Int J Mol Sci. 2023 Sep 3;24(17):13618. doi: 10.3390/ijms241713618.
The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.
Kerr KM, Bibeau F, Thunnissen E, Botling J, Ryška A, Wolf J, Öhrling K, Burdon P, Malapelle U, Büttner R.
Lung Cancer. 2021 Apr;154:161-175. doi: 10.1016/j.lungcan.2021.02.026. Epub 2021 Feb 22.
Strategies for targeting undruggable targets.
Zhang G, Zhang J, Gao Y, Li Y, Li Y.
Expert Opin Drug Discov. 2022 Jan;17(1):55-69. doi: 10.1080/17460441.2021.1969359. Epub 2021 Aug 30.
Degraders in epigenetic therapy: PROTACs and beyond.
Dai XJ, Ji SK, Fu MJ, Liu GZ, Liu HM, Wang SP, Shen L, Wang N, Herdewijn P, Zheng YC, Wang SQ, Chen XB.
Theranostics. 2024 Jan 27;14(4):1464-1499. doi: 10.7150/thno.92526. eCollection 2024.
Targeted Radiotherapeutics from 'Bench-to-Bedside'.
Müller C, Béhé M, Geistlich S, van der Meulen NP, Schibli R.
Chimia (Aarau). 2020 Dec 23;74(12):939-945. doi: 10.2533/chimia.2020.939.
The Ill Returning Traveler.
Rathjen NA, Shahbodaghi SD.
Am Fam Physician. 2023 Oct;108(4):396-403.
The burden, causes, and determinants of blindness and vision impairment in Asia: An analysis of the Global Burden of Disease Study.
Zou M, Chen A, Liu Z, Jin L, Zheng D, Congdon N, Jin G.
J Glob Health. 2024 Jun 14;14:04100. doi: 10.7189/jogh.14.04100.
Polypharmacology: new drugs in 2023-2024.
Ryszkiewicz P, Malinowska B, Schlicker E.
Pharmacol Rep. 2025 Jun;77(3):543-560. doi: 10.1007/s43440-025-00715-8. Epub 2025 Mar 17.
